



Index

Note: Page numbers of article titles are in **boldface** type.

A

- Acromegaly, secondary osteoporosis from, 122
- Acute phase reaction, to bisphosphonates, 262
- Adolescence, bone mass accrual during, 42–48, 55, 115, 343
bone strength development during, 29–31
calcium and vitamin D intake recommendations for, 342–345, 348
phytoestrogens safety for, 249
- Adrenal androgens, bone metabolism and, 210–211
- Adrenalectomy, bone metabolism after, 210
- Age and aging, as bone mass accrual factor, 42–48, 55
as osteoporosis risk factor, 1–4
 based on calcium and vitamin D intake, 342–345, 348
 impact on biochemical bone markers, 92
 in geriatric population, 8–10, 343
bone strength with, developmental stages of, 27–31
 loss of, 25–26, 31–36
 physiologic processes impacting, 25, 36–37
- Alcohol intake, as osteoporosis risk factor, 8, 125–126
as peak bone mass factor, 56–57
- Alendronate, for osteoporosis, glucocorticoid-induced, 145
 guidelines for, 255–258
 postmenopausal, calcitonin therapy and, 281
 with parathyroid hormone, 297
- Alkaline phosphatase (ALP), as biochemical bone marker, 84–85, 236–238
- Allele-sharing studies, of osteoporosis genes, 67–68
 quantitative trait loci in, 69–71
- Alpha-estrogen receptors, deficiency in men, bone metabolism and, 196
 genetic knockout models of, 200–203
gene for, osteoporosis susceptibility based on, 74–75
phytoestrogen mechanism of action through, 235–236
- Amenorrhea, in athletes, secondary osteoporosis from, 118
- Anabolic therapy(ies), in osteoporosis, **285–307**
 bisphosphonates with, 264
 conceptual basis for, 285, 300
 fluoride as, 286–287
 glucocorticoid-induced, 147
 growth hormone as, 287–288
 insulin-like growth factor as, 287–288
 parathyroid hormone as, as combination with alendronate, 297
 as combination with estrogen, 295–296
 as monotherapy post menopause, 292
 concerns about, 299–300
 continuous versus intermittent, 291–292
 in glucocorticoid-induced osteoporosis, 297
 in men, 292–295
 withdrawal of, 298
- Analgesia, calcitonin as, 279–280
- Analytical variability, of bone marker measurements, 88–91
- Androgen insensitivity syndrome (AIS), secondary osteoporosis from, 120, 208–209

- Androgens, bone metabolism role of, **195–218**
 clinical summary of, 195–196, 213
 gender non-specificity of, 212–213
 in women, 208–212
- Animal studies, of osteoporosis genes, 68–69
- Anorexia, secondary osteoporosis from, 117–119
- Anti-resorptive agents, for osteoporosis, 253–271. See also *specific drug*.
 combining with other treatments, 264
 dosing of, 260
 duration of therapy, 265
 fracture risk reduction with, 255–257
 glucocorticoid-induced, 144–146, 149
 in special clinical circumstances, 262–264
 mechanism of actions, 253–254
 monitoring response to, 265
 rationale for, 127, 253–254, 265–266, 290–291, 347
 side effects of, 260–261
 skeletal effects of, 253–255
 specific drugs, 255–260
 surrogate end-point markers for, 170–176
 tolerability of, 260–261
- Anticonvulsants, secondary osteoporosis from, 130–131
- Apolipoprotein E, osteoporosis susceptibility based on, 76
- Aromatase deficiency, in men, bone metabolism and, 196–200
 genetic knockout models of, 200–203
- Ash density, as bone load capacity factor, 27–29
- Association studies, of osteoporosis genes, candidate, 67–68, 72–77
- Athletes, with amenorrhea, secondary osteoporosis in, 118
- B**
-
- Basic multicellular unit (BMU), in aging bone remodeling, 25, 31–32, 36–37
- Bazedoxifene, for postmenopausal osteoporosis, 230
- Behavior, as peak bone mass factor, 52–57
- Bending strength/stress, as bone load capacity factor, 26–28
- Beta-estrogen receptors, deficiency in men, genetic knockout models of, 201–203
 phytoestrogen mechanism of action through, 235–236
- Biliary cirrhosis, primary, secondary osteoporosis from, 125
- Biochemical bone markers, aging effects on, 92
 basic biochemistry of, formation, 84–85, 87
 resorption, 86–88
 in osteoporosis, 92–105
 bone loss prediction with, 94–97
 current trials on, 92–93
 fracture risk prediction with, 97–99, 104
 of bone remodeling, 93–94
 therapy and, 99–105
 measurement variability with, 88–91
 menopause effects on, 92
 nasal spray calcitonin impact on, 277–278
 of formation versus resorption, 84–88
 phytoestrogens impact on, 241–245
 clinical trials on, 246–249
 caveats in interpretations of, 241
 synthetic agents, 249–250
- Biomechanical basis, of bone strength, **25–38**
 developmental growth stages of, 27–28, 31–36
 fragility fractures and, 25–26, 36–37
 in aging bones, 25, 31–36
 in periosteal and endosteal surfaces, 30–31
 in young bones, 27–32
 key concepts in, 25–26, 36–37
 “right stuff” for functional, 26–29, 36
- Biphosphonates, for osteoporosis, **253–271**.
 See also *specific drug*.
 clinical trials of, 175–176
 combining with other treatments, 264
 dosing of, 260
 duration of therapy, 265
 fracture risk reduction with, 255–257
 glucocorticoid-induced, 144–146, 149

- in special clinical circumstances, 262–264
 - mechanism of actions, 253–254
 - monitoring response to, 175, 265
 - rationale for, 127, 253–254, 265–266, 290–291, 347
 - side effects of, 260–261
 - skeletal effects of, 253–255
 - specific drugs, 255–260
 - surrogate end-point markers for, 170–176
 - tolerability of, 260–261
- Bone densitometry, clinical utility and application of, **159–180**
 - for disease progression and therapy monitoring, 170–176
 - for fracture risk prediction, 166–170
 - for osteoporosis diagnosis by WHO criteria, 159–166
 - standard deviation scores in, 159–160, 162–165, 169
 - T score variances in, 160–165
- Bone formation, biochemical markers of, basics of, 85, 87
 - bone remodeling versus, 84–86
 - biphosphonates impact on, 261–262
 - fragility with failure of, 25–26, 31–36
 - with osteoporosis, 16, 18–20
- Bone fragility, biomechanical basis of, 25–26
 - in aging bones, 31–36
- Bone loss, with osteoporosis, biochemical markers of, 94–97
- Bone markers. See *Biochemical bone markers*.
- Bone marrow, disorders of, secondary osteoporosis from, 129
 - transplantation of, secondary osteoporosis from, 127
- Bone mass, accrual factors of, 41–46
 - determinants of, 46–57
 - low, with osteoporosis, 16
 - peak. See *Peak bone mass*.
 - regulation of, osteoporosis genes and, 69–71
- Bone measurement techniques, for mineral content, 39–41
 - for mineral density. See *Bone densitometry*.
 - for osteoporosis, 2–3, 141
 - for peak bone mass, 41, 43, 45–48
- Bone metabolism, sex steroids role in, 195–196, 213
 - gender non-specificity of, 212–213
 - in men, 196–208
 - in women, 208–212
- Bone mineral content (BMC), as bone load capacity factor, 27–29
 - in aging bones, 25–26
 - measurement techniques for, 39–41
- Bone mineral density (BMD), anabolic therapy impact on, 286–300
 - conceptual basis for, 285, 300
 - fluoride, 286–287
 - growth hormone, 287–288
 - insulin-like growth factor, 287–288
 - parathyroid hormone,
 - as combination with alendronate, 297
 - as combination with estrogen, 295–296
 - as monotherapy post menopause, 292
 - concerns about, 299–300
 - continuous versus intermittent, 291–292
 - in glucocorticoid-induced osteoporosis, 297
 - in men, 292–295
 - withdrawal of, 298
- as bone load capacity factor, 27–30
 - drugs for enhancing, 37
 - in aging bones, 33–36
- bone mineral content versus, 40
- calcitonin impact on, injectable, 273–274
 - nasal spray, 274–275
- clinical utility and application of, **159–180**
 - for disease progression and therapy monitoring, 170–176
 - for fracture risk prediction, 166–170
 - for osteoporosis diagnosis by WHO criteria, 159–166
- genetic determinants of, 65–77
- measurement of. See *Bone densitometry*.
- phytoestrogens impact on, 241–245
 - clinical trials on, 246–249
 - caveats in interpretations of, 241
 - synthetic agents, 249–250
- selective estrogen receptors modulators impact on, 221–223

- Bone mineral density (*continued*)
 sex steroids role in, 195–213
 gender non-specificity of, 208–213
 in men, 196–208
 in women, 208–212
- Bone morphogenetic proteins (BMPs), in
 bone formation regulation, 19–20
- Bone remodeling, biochemical markers of,
83–113
 aging effects on, 92
 basics of, 86–88
 bone formation versus, 84–86
 in osteoporosis, 92–105
 measurement variability with,
 88–91
 menopause effects on, 92
 bone formation impairment during, 20
 in aging bones, 25–26
 failure of, 31–36
 reduction of rate of, 37
 with osteoporosis, 16–18, 342
 anabolic therapy impact on, 285,
 300
 biochemical markers of, 92–105
 bisphosphonates impact on,
 253–255, 257
 glucocorticoid-induced, 139–140
- Bone remodeling units (BRU), coupling
 defects of, 20–21
- Bone replacement. See *Bone turnover*.
- Bone resorption. See *Bone remodeling*.
- Bone sialoprotein (BSP), as biochemical
 bone marker, 86, 88
- Bone-specific alkaline phosphatase (BSAP),
 anabolic therapy impact on, 289–290
 as biochemical bone marker, 84–85,
 211
- Bone strength, structural and biomechanical
 basis of, **25–38**
 developmental growth stages of,
 27–28, 31–36
 in aging bones, 25, 31–36
 in periosteal and endosteal
 surfaces, 30–31
 in young bones, 27–32
 key concepts in, 25–26, 36–37
 “right stuff” for functional,
 26–29, 36
- Bone turnover (BMC), anti-resorptive
 therapy surrogate markers for,
 170–176
 during aging, 25–26
 in osteoporosis, anabolic therapy
 impact on, 286–300
 biochemical markers of, 92–105
 pre-treatment role of,
 100–101
 predictions based on,
 92–100
 therapeutic monitoring role
 of, 101–105
 monogenic bone disease impact
 on, 69–70
 nasal spray calcitonin impact on,
 277–278
 selective estrogen receptors
 modulators impact on, 102,
 220–221
- Breaking strength/stress, bone capacity for,
 26–28
- Breast, selective estrogen receptors
 modulators impact on, 228–229
- Bulk, as bone load capacity factor, 26
-
- C**
- Calcitonin, **273–284**
 administration of, 280
 analgesic effects of, 279–280
 for osteoporosis, early menopausal,
 275–277
 glucocorticoid-induced, 143–144,
 278–279
 in combination therapy, 281
 postmenopausal, 273–275, 282
 in bone resorption regulation, 17–18
 injectable, for postmenopausal
 osteoporosis, 273–274
 nasal spray, effect on bone turnover
 markers, 277–278
 effect on fracture reduction,
 275–278
 effect on menopausal
 osteoporosis, 274–277
 for men with idiopathic
 osteoporosis, 278
 physiology of, 273
 resistance to, 280–281
 side effects of, 280
 therapeutic indications for, 273
- Calcitriol, role in vitamin D absorption,
 340–342
- Calcium, deficiency of, bone remodeling
 and, 92
 secondary osteoporosis from,
 117–119, 122–123
 dietary, as peak bone mass factor,
 53–56
 intake recommendations for,
 344–345

- sources of, 348
 - for osteoporosis, **339–352**
 - glucocorticoid-induced, 142–143
 - natural versus supplemental sources of, 348
 - physiology of, 339–340
 - preventive guidelines for, 342–345
 - supportive guidelines for, 345–348
 - retention of during adolescence, 343–344
 - Calcium supplements, 92, 348–349
 - Candidate genes, as peak bone mass factor, 49–50
 - osteoporosis susceptibility based on, association studies of, 72–77
 - polymorphisms of other, 77
 - Cardiovascular disease, selective estrogen receptors modulators impact on, 226–227
 - Cbfa-1/Runx-2, in bone formation regulation, 19
 - Celiac disease, secondary osteoporosis from, 123
 - Children, osteoporosis risks in. See also *Adolescence*.
 - biphosphonates for, 263
 - Chromosomes, as peak bone mass factor, 49
 - osteoporosis susceptibility based on, 69–77
 - Coefficient of variation percentage (CV%), in bone marker measurements, 173–174
 - Collagen propeptides, as biochemical bone markers, of formation, 84–85, 87
 - of resorption, 86–88, 90–95, 99–104
 - Collagen type I alpha 1 gene, osteoporosis susceptibility based on, 71, 73–74
 - Combination therapy, for osteoporosis, calcitonin, 281
 - parathyroid hormone, 295–297
 - Computed tomography (CT), for osteoporosis. See *Quantitative computed tomography (QCT)*.
 - quantitative, as bone measurement technique, for age-related osteoporosis, 2–3
 - Connectivity, loss of, in aging bones, 33–34, 36
 - Cortical bone, aging remodeling of, 28–33, 35–36
 - gender differences in, 167–168
 - Coupling defects, in osteoporosis pathogenesis, 20–21
 - Cross section area (CSA), in aging bone remodeling, 25, 30, 32, 36
 - Crosslinked telopeptides, as biochemical bone marker, 86, 88
 - CTX level, as variable, in bone marker measurements, 90–91
 - with calcitonin therapy, 276–278, 280
 - Cytokines, in bone resorption regulation, 17
- ## D
-
- Daidzein, as phytoestrogen source, 234
 - bone mineral density and, clinical trials on, 247–248
 - mechanism of action, 235–236, 239
 - Deoxyypyridinoline (DPD), as biochemical bone marker, 86–88, 91–92, 95, 97, 101
 - Developmental growth stages, of bone strength, 27–28, 31–36
 - DHEA therapy, for women with osteoporosis, 211
 - Diabetes, secondary osteoporosis from, 121
 - Dietary calcium, as peak bone mass factor, 53–56
 - Dietary supplements, for osteoporosis, 92, 348–349
 - phytoestrogens as, 233–234
 - binding affinity to estrogen receptors, 235–236
 - Dihydrotestosterone, bone metabolism role of, in men, 196, 204–208
 - in women, 209, 212
 - Droloxifene, for postmenopausal osteoporosis, 229
 - Dual energy x-ray absorptiometry (DXA), as measurement technique for osteoporosis, 40–41
 - age-related, 2
 - gender-related, 196
 - glucocorticoid-induced, 140
 - WHO criteria for, 160–166
 - with anti-resorptive agent surrogate markers, 173–175

E

- Early menopause, osteoporosis risks with, calcitonin therapy for, 275–277
- Eating disorders, secondary osteoporosis from, 117–119
- Ehlers-Danlos syndrome, secondary osteoporosis from, 116, 128
- Elasticity, as bone load capacity factor, 26–27
- Elderly patients. See *Geriatric population*.
- Endocrine disorders, osteoporosis from, 16
secondary osteoporosis from, 116, 120–122
- Endosteal bone, development of surface strength of, 30–31, 36
- Environment, as peak bone mass factor, 52–57
- Enzymes, as biochemical markers, of bone remodeling, 83–88
- Estradiol, bone metabolism role of, in men, 196, 204–208
phytoestrogen similarity to, 235
- Estrogen deficiency, osteoporosis from, 16, 21, 33
in men, 199–200
premenopausal secondary, 115–116, 118–120
- Estrogen receptors, alpha, deficiency in men, bone metabolism and, 196
genetic knockout models of, 200–203
gene for, osteoporosis susceptibility based on, 74–75
phytoestrogen mechanism of action through, 235–236
beta, deficiency in men, genetic knockout models of, 201–203
phytoestrogen mechanism of action through, 235–236
- Estrogen replacement therapy (ERT), for men, with aromatase deficiency, 199, 201
for postmenopausal osteoporosis, 137, 281, 291
biphosphonate therapy with, 264
bone markers of, 100–101
calcium and vitamin D intake with, 340, 346–347
glucocorticoid-induced, 144
limitations of, 219, 340
phytoestrogens impact on,

240–242
with parathyroid hormone, 295–296

- Estrogens, bone metabolism role of, **195–218**
clinical summary of, 195–196, 213
gender non-specificity of, 212–213
in men, 196–208
alpha-estrogen receptor deficiency, 196
animal “knockouts” of genes, 200–203
aromatase deficiency, 196–200
studies in adults, 204–208
- Estrone, bone metabolism role of, in men, 196, 204–208
- Ethnicity, as bone strength factor, 31
as fracture risk factor, 168–170
as osteoporosis risk factor, 5–8
biphosphonate indications, 263
genetics of, 74, 76
as peak bone mass factor, 42–44, 50–52
- Etidronate, for osteoporosis, guidelines for, 256, 258–259
- “Experiments of nature,” for bone metabolism, in men, 196–208
alpha-estrogen receptor deficiency, 196
animal “knockouts” of genes, 200–203
aromatase deficiency, 196–200
studies in adults, 204–208
in women, 208–212
challenges to, 208–209
studies in adults, 210–212
studies in animals, 209–210

F

- Femoral neck, bone mineral density of, in osteoporosis definition, 1–2, 4–8
sex and racial differences in, 30–31, 167–168, 211
- Flavonoids. See *Isoflavones*.
- Flaxseed, as phytoestrogen source, 235, 249
- Flexibility, as bone load capacity factor, 26–28
- Fluoride, as anabolic therapy, for osteoporosis, 286–287
for osteoporosis, glucocorticoid-induced, 147

- Follicle-stimulating hormone (FSH), bone metabolism role of, in men, 196–197, 200
- Food and Drug Administration (FDA), on anti-resorptive agent surrogate markers, for postmenopausal osteoporosis, 171–176
- Force, aging bones capacity for, 25–26
- Fracture(s), fragility, biomechanical basis of, 25–26, 36–37
 - in aging bones, 31–36
 - osteoporosis risks for, 15, 18
 - biochemical bone markers of, 97–99, 104
 - biphosphonates impact on, 255–257
 - bone densitometry prediction of, 166–170
 - calcitonin impact on, injectable, 274
 - nasal spray, 275–278
 - glucocorticoid-induced, 137–138
 - selective estrogen receptors modulators impact on, 223–226
 - worldwide epidemiology of, 1–10
- Functional loading, adaptation to, osteoporosis and, 21
-
- G**
- Galactosyl hydroxylysine (GHL), as biochemical bone marker, 86–87
- Gastrectomy, secondary osteoporosis following, 123–124
- Gastrointestinal disease, secondary osteoporosis from, 116, 122–125
- Gastrointestinal metabolism, of phytoestrogens, 240
- Gastrointestinal system, biphosphonates impact on, 260–261
- Gaucher disease, secondary osteoporosis from, 129
- Gender, as bone strength factor, 29–31
 - during aging, 31–36
 - as fracture risk factor, 167–169
 - as osteoporosis risk factor, 4–5
 - as peak bone mass factor, 42–43, 45–48, 55
 - bone metabolism based on, clinical summary of, 195–196, 213
 - in men, 196–208
 - in women, 208–212
 - non-specificity of, 212–213
 - cortical bone differences based on, 167–168
- Genetics and genetic mutations, as peak bone mass factor, 46, 49–50
 - of bone formation regulation, 19–20
 - of bone metabolism, in men, animal “knockout” models of, 200–203
 - of bone strength, 29–31
 - of osteoporosis, **65–81**
 - approaches to gene identification, 66–69
 - association studies of candidate genes, 72–77
 - bone formation and, 19–20, 46, 49–50, 65–66
 - clinical practice implications, 77
 - quantitative trait loci for bone mass regulation, in humans, 69–71
 - in mice, 71
 - secondary, 116, 120, 127–128
 - single-gene disorders, 66
 - bone mass abnormalities and, 69
- Genistein, as phytoestrogen source, 234
 - bone markers and, 239–240, 245
 - bone mineral density and, clinical trials on, 247–248
 - mechanism of action, 235–236
- Geriatric population, osteoporosis risks in, 8–10, 343
 - biphosphonates for, 262–263
- Glucocorticoid-induced osteoporosis (GIOP), **135–157**
 - calcitonin for, 143–144, 278–279
 - calcium and vitamin D for, 141–143
 - diagnostic evaluation of, 140–141
 - dose correlations, 137–139
 - epidemiology of, 135–139
 - in high-risk users, 148–149
 - parathyroid hormone for, 297
 - pathogenesis of, 139–140
 - prevention of, 141–148
 - secondary, 122
 - thiazide diuretics for, 143
 - treatment of, agents for, 141–148
 - patterns and recommendations for, 147–149
 - with rheumatic diseases, 129
- Gonadotropins, as peak bone mass factor, 42–48, 55
 - bone metabolism role of, in men, 196, 204–208
 - secondary osteoporosis and, 115, 127

Granulocyte macrophage colony-stimulating factor (GM-CSF), in bone resorption regulation, 18

Growth factors. See *Growth hormone (GH)*.

Growth hormone (GH), as peak bone mass factor, 55
for osteoporosis, 287–288
glucocorticoid-induced, 147

Growth stages, developmental, of bone strength, 27–28, 31–36

H

Hematologic disorders, secondary osteoporosis from, 116–117

Hemochromatosis, secondary osteoporosis from, 121–122

Heparin, secondary osteoporosis from, 131

Hepatic disease, secondary osteoporosis from, 124–125

Herbal preparations, binding affinity to estrogen receptors, 236

HMG coenzyme A reductase inhibitors, as anabolic therapy, for osteoporosis, 290–291

Homocystinuria, secondary osteoporosis from, 116, 128

Hormonal status. See also *specific hormone*.
as peak bone mass factor, 55, 115, 203

Hormone replacement therapy (HRT). See *specific hormone*.

Hydroxyproline (Hyp), as biochemical bone marker, 86–88

Hyperparathyroidism, secondary osteoporosis from, 122, 126

Hyperprolactinemia, secondary osteoporosis from, 119

Hypogonadism, secondary osteoporosis from, 115–116, 118–120

I

Ibandronate, for osteoporosis, guidelines for, 259

Idiopathic osteoporosis, in men, calcitonin for, 278
in women, bisphosphonates for, 263

Idoxifene, for postmenopausal osteoporosis, 229

Immobilization, bisphosphonate indications for, 264

Impact loading, bone capacity for, 26–29

Inflammatory bowel disease, secondary osteoporosis from, 124

Inflammatory reactions, to bisphosphonates, 262

Insulin-like growth factor-1 (IGF-1), as anabolic therapy, for osteoporosis, 287–288, 291
glucocorticoid-induced osteoporosis and, 139
in bone formation regulation, 19, 94, 246

Interleukin-1 gene cluster, osteoporosis susceptibility based on, 75–76

Interleukin-6, osteoporosis susceptibility based on, 76, 208

Interleukins (ILs), in bone resorption regulation, 17–18, 208

Ipriflavone, bone mineral density and, 249–250

Isoflavones, as phytoestrogen source, 234
bone mineral density and, 241–245
clinical trials on, 246–249
mechanism of action, 235–236
synthetic, effects on bone markers and density, 249–250

J

Juvenile osteoporosis, bisphosphonates for, 263

K

Kidney transplantation, secondary osteoporosis from, 126

Klinefelter syndrome, secondary osteoporosis from, 119

Knockout models, genetic, of men's bone metabolism, 200–203

L

Laboratory evaluation, as variable, in bone marker measurements, 91
of osteoporosis,
glucocorticoid-induced, 141
secondary, 132–133

Lasofoxifene, for postmenopausal osteoporosis, 230

- Least significant change, in bone marker measurements, 91, 173, 175
- Leptin, in bone formation regulation, 20
- Leukemias, secondary osteoporosis from, 129
- Levomeloxifene, for postmenopausal osteoporosis, 229–230
- Lifestyle, as peak bone mass factor, 55–57
- Ligans, as phytoestrogen source, 234–235, 240, 249
- Linkage analysis, in human pedigrees, for osteoporosis genes, 66–67
- Linkage disequilibrium (LD), of osteoporosis genes, 68
- Lipid profile, selective estrogen receptors modulators impact on, 226–227
- Lipoprotein receptor-related protein-5 (LFP-5), in bone formation regulation, 20
- Liver function, secondary osteoporosis and, 124–125
- Liver transplantation, secondary osteoporosis from, 126–127
- Load and loading, bone capacity for, aging effects on, 25–26, 32, 35–36
compressive, 30
impact, 26–29
material and structure for functional, 26–28
sex and gender differences in, 29–31, 35–36
- LOD score, osteoporosis susceptibility based on, 67, 69–71
- Lumbar spine, bone mineral density of, in osteoporosis definition, 3–5, 7–8
- Luteinizing hormone (LH), bone metabolism role of, in men, 196–197
- Lymphomas, secondary osteoporosis from, 129
- M**
-
- Macrophage colony-stimulating factor (M-CSF), in bone resorption regulation, 16–17
- Magnetic resonance imaging (MRI), as bone measurement technique, 40–41
- Malignancy(ies), of bone marrow, secondary osteoporosis from, 129
- Marfan syndrome, secondary osteoporosis from, 116, 128
- Mastocytosis, systemic, secondary osteoporosis from, 130
- Measurement variability, of bone marker measurements, 88–91
- Medications, for bone remodeling reduction, 37
secondary osteoporosis from, 117, 130–131
- Menopause, osteoporosis after. See *Postmenopausal osteoporosis*.
- Meta-analysis, on anti-resorptive agent surrogate markers, for postmenopausal osteoporosis, 172–173
- Metabolism, bone, sex steroids role in, 195–196, 213
gender non-specificity of, 212–213
in men, 196–208
in women, 208–212
gastrointestinal, of phytoestrogens, 240
mineral, biphosphonates impact on, 262
- Methotrexate, secondary osteoporosis from, 131
- Mineral metabolism, biphosphonates impact on, 262
- Molecular markers, of bone. See *Biochemical bone markers*.
- Monofluorophosphate (MFP), as anabolic therapy, for osteoporosis, 286
- Mouse/mice studies, of osteoporosis genes, 68–69, 71
- Multiple myeloma, secondary osteoporosis from, 129
- N**
-
- Nasal spray calcitonin. See *Calcitonin*.
- National Health and Nutrition Examination Survey (NHANES III), Third, on osteoporosis, age-related, 2–5, 344
bone densitometry and, 162, 167–169
- National Osteoporosis and Risk Assessment (NORA), clinical utility of, 160–161, 166–167

Nutritional deficiencies, secondary
osteoporosis from, 117–119,
122–123

O

Orchidectomy, bone metabolism after, 203,
209

Organ transplantation, osteoporosis from,
biphosphonates for, 264
secondary, 125–127

Osteoblasts, glucocorticoid-induced
osteoporosis and, 139
in bone resorption regulation, 16–20,
33, 37
phytoestrogens impact on, 236–238
with osteoporosis, anabolic therapy
impact on, 285, 290, 300
sex steroids impact on, 212–213

Osteocalcin (OC), as biochemical bone
marker, 84–85, 90, 92, 94, 96, 98–100
gender differences in, 206–207

Osteoclasts, calcitonin impact on, 273
in bone resorption regulation, 16–18,
20, 33, 37
biphosphonates impact on,
253–254
phytoestrogens impact on, 237–240
with osteoporosis, anabolic therapy
impact on, 285, 290, 300

Osteogenesis imperfecta (OI), secondary
osteoporosis from, 66, 116, 127–128

Osteoporosis, after menopause. See
Postmenopausal osteoporosis.
anabolic therapies in, **285–307**
conceptual basis for, 285, 300
fluoride as, 286–287
growth hormone as, 287–288
insulin-like growth factor as,
287–288
parathyroid hormone as, as
combination with
alendronate, 297
as combination with
estrogen, 295–296
as monotherapy post
menopause, 292
concerns about, 299–300
continuous versus
intermittent, 291–292
in glucocorticoid-induced
osteoporosis, 297
in men, 292–295
withdrawal of, 298
statins as, 290–291
strontium as, 288–290

tibolone as, 291
biochemical bone markers of, 92–105
bone loss prediction with, 94–97
current trials on, 92–93
fracture risk prediction with,
97–99, 104
of bone remodeling, 93–94
therapy and, 99–105
biphosphonates for, **253–271**
combining with other treatments,
264
dosing of, 260
duration of therapy, 265
fracture risk reduction with,
255–257
glucocorticoid-induced, 144–146,
149
in special clinical circumstances,
262–264
mechanism of actions, 253–254
monitoring response to, 265
rationale for, 127, 253–254,
265–266, 290–291, 347
side effects of, 260–261
skeletal effects of, 253–255
specific drugs, 255–260
tolerability of, 260–261
bone densitometry for diagnosis by
WHO criteria, 159–166
bone remodeling with, 16–18, 342
anabolic therapy impact on, 285,
300
biochemical markers of, 92–105
glucocorticoid-induced, 139–140
bone turnover in, anabolic therapy
impact on, 286–300
biochemical markers of, 92–105
predictions based on,
92–100
pretreatment role of,
100–101
therapeutic monitoring role
of, 101–105
monogenic bone disease impact
on, 69–70
calcitonin therapy for, early
menopausal, 275–277
glucocorticoid-induced, 278–279
in combination therapy, 281
postmenopausal, 273–275, 282
calcium and vitamin D for, **339–352**
as therapeutic support, 345–348
physiology of, 339–342
preventive guidelines, 342–345
sources of, 348–349
definition of, 15, 219
epidemiology worldwide, **1–13**
age factor, 1–4
ethnicity factor, 5–8

- future prospects for, 9–10
 - gender factor, 4–5
 - other risk factors, 8–9
 - World Health Organization on, 1, 4–5
 - fracture risk with, 15, 18
 - bone mineral density prediction for, 166–170
 - selective estrogen receptors modulators impact on, 223–226
 - genetic determinants of, **65–81**
 - approaches to identification of, 66–69
 - association studies of candidate genes, 72–77
 - bone formation and, 19–20, 46, 49–50, 65–66
 - clinical practice implications, 77
 - quantitative trait loci for bone mass regulation, in humans, 69–71
 - in mice, 71
 - single-gene disorders, 66
 - bone mass abnormalities and, 69
 - glucocorticoid-induced. See *Glucocorticoid-induced osteoporosis*.
 - idiopathic, bisphosphonates for, 263
 - calcitonin for, 278
 - pathogenesis of, **15–24**
 - adaptation to functional loading in, 21
 - bone formation regulation and, 16, 18–20
 - bone resorption regulation and, 16–18
 - coupling defects in, 20–21
 - multiple pathways in, 15–17, 21
 - three major reasons for, 16
 - primary, 16, 115. See also *Primary osteoporosis*.
 - secondary, 115. See also *Secondary osteoporosis*.
 - therapeutic response monitoring for, 170–176
- Osteoporosis-pseudoglioma syndrome (OPS), 66, 69
- Osteoprotegerin (OPG), 208, 237
- Osterix, in bone formation regulation, 19
- Ovarian function, endogenous, phytoestrogens impact on, 240–241
- P**
-
- Pain, calcitonin analgesia for, 279–280
- Pamidronate, for osteoporosis, glucocorticoid-induced, 145
 - guidelines for, 259
- Pancreatic insufficiency, secondary osteoporosis from, 124
- Parathyroid hormone (PTH), as anabolic therapy, for osteoporosis, as combination with alendronate, 264, 297
 - as combination with estrogen, 295–296
 - as monotherapy post menopause, 292
 - calcium intake and, 348
 - concerns about, 174, 299–300
 - continuous versus intermittent, 291–292
 - glucocorticoid-induced, 147–148, 297
 - in men, 292–295
 - withdrawal of, 298
- in bone resorption regulation, 17–18, 242, 342
- Peak bone mass (PBM), **39–64**
 - bone mass accrual and, 41–46
 - critical years of increments of, 42–44
 - gender differences with, 42–43, 45–48, 55
 - importance of, 41–42
 - tracking of, 45–46
 - bone measurement techniques for, 39–41
 - determinants of, 46–57
 - dietary calcium as, 53–56
 - ethnicity as, 42–44, 50–52
 - heredity as, 46, 49–50
 - hormonal status as, 55, 203
 - lifestyle as, 55–57
 - physical activity as, 52–54
 - indications for study of, 39
- Peptides, as biochemical markers, of bone remodeling, 83–88
- Periosteal bone, apposition during aging, 31–32, 36
 - development of surface strength of, 30–31
 - formation during aging, 35
- Phenotypes, osteoporosis susceptibility based on, 66–77
- Photolysis, as variable, in bone marker measurements, 90
- Physical activity, as peak bone mass factor, 52–54

- Phytoestrogens, **233–252**
 as dietary supplements, 233–234
 classification of, 234–235
 clinical trials on, bone marker and bone mineral density effects, 246–249
 caveats in interpretations of, 241
 effects of, on bone markers, 241–245
 of synthetic agents, 249–250
 on bone mineral density, 241–245
 clinical trials on, 246–249
 on endogenous ovarian function, 240–241
 on osteoblasts, 236–238
 on osteoclasts, 237–240
 synthetic isoflavones, 249–250
 gastrointestinal metabolism of, 240
 mechanism of action, 235–236
 synthetic agents, 249–250
- Polycystic ovary syndrome (PCOS), bone metabolism and, 210
- Postmenopausal osteoporosis (PMO), anti-resorptive agent surrogate markers for, 171–176
 primary, bone remodeling markers and, 32–33, 157
 calcitonin for, 273–275, 282
 early administration of, 275–277
 definition of, 16, 115
 parathyroid hormone for prevention of, 292
 phytoestrogens impact on, 234
 bone mineral density and, 241–245
 clinical trials on, 246, 248–249
 mechanism of action, 235–236
 ovarian function and, 240–241
 selective estrogen receptors modulators for, **219–232**
 bone mineral density effects, 221–223
 bone turnover effects, 102, 220–221
 clinical interest in, 219–220
 extraskeletal effects, 226–229
 fracture risk effects, 223–226
 new developments, 229–230
- Pre-analytical variability, of bone marker measurements, 88–90
- Prednisone, secondary osteoporosis from.
 See *Glucocorticoid-induced osteoporosis (GIOP)*.
- Pregnancy, secondary osteoporosis from, 130
- Premenopausal women, osteoporosis risks in, bisphosphonates for, 263
- Prevent Recurrence of Osteoporotic Fracture (PROOF) Study, 276–278, 280
- Primary biliary cirrhosis (PBC), secondary osteoporosis from, 125
- Primary osteoporosis, postmenopausal, anti-resorptive agent surrogate markers for, 171–176
 bone remodeling markers and, 32–33, 157
 calcitonin for, 273–275, 282
 definition of, 16, 115
 parathyroid hormone for prevention of, 292
 phytoestrogens impact on, 234
 bone mineral density and, 241–245
 clinical trials on, 246, 248–249
 mechanism of action, 235–236
 ovarian function and, 240–241
 selective estrogen receptors modulators for, **219–232**
 bone mineral density effects, 221–223
 bone turnover effects, 102, 220–221
 clinical interest in, 219–220
 extraskeletal effects, 226–229
 fracture risk effects, 223–226
 new developments, 229–230
- Procollagen propeptides, as biochemical bone markers, 84–85, 87, 90–95, 99–104
- Proliferation disorders, of bone marrow, secondary osteoporosis from, 129
- Puberty. See *Adolescence*.
- Pyridinoline (PYD), as biochemical bone marker, 86–88, 95

Q

- Quantitative computed tomography (QCT), as bone measurement technique, 40, 50
 for osteoporosis, age-related, 2–3
 glucocorticoid-induced, 141

- with anti-resorptive agent surrogate markers, 173
for peak bone mass, 41, 43, 45–48
- Quantitative trait loci (QTL), for bone mass regulation, in humans, 69–71
in mice, 71
-
- R**
- Race. See *Ethnicity*.
- Raloxifene, for postmenopausal osteoporosis, adverse events from, 229
biphosphonate therapy with, 264
bone mineral density effects, 223
bone turnover effects, 102, 104, 220–221
calcitonin therapy and, 281
calcium and vitamin D intake with, 347–348
clinical interest in, 219–220
extraskeletal effects, 226–229
fracture risk effects, 224–226
- Rat studies, of osteoporosis, with testicular feminization, 209–210
- Receiver operating curves (ROC), in osteoporosis measurement, 166–167
- Receptor activator of NFK B ligand (RANKL), in bone resorption regulation, 16–17, 208, 237, 291
- Recombinant human PTH (rhPTH), for osteoporosis, calcium intake and, 348
- Rectifier K⁺current, in phytoestrogen actions, 237, 239
- Renal insufficiency, osteoporosis from, biphosphonate indications for, 263–264
secondary, 126
- Rheumatic disease, secondary osteoporosis from, 117, 128–129
- Risedronate, for osteoporosis, bone remodeling effects, 101, 105
glucocorticoid-induced, 145–146
guidelines for, 256, 258
-
- S**
- Salmon calcitonin. See *Calcitonin*.
- Sample collection mode, as variable, in bone marker measurements, 90–91
- Sclerostin, in bone formation regulation, 20
- Secondary osteoporosis, **115–134**
causes of, 115–117
definition of, 115
diagnostic evaluation for, 132–133
from bone marrow disorders, 129
from endocrine disorders, 116, 120–122
from gastrointestinal disease, 116, 122–125
from hypogonadism, 115–116, 118–120
from inherited skeletal disorders, 127–128
from medications, 117, 130–131
from organ transplantation, 125–127
from pregnancy, 130
from premenopausal estrogen deficiency, 115–116, 118–120
from rheumatic disease, 117, 128–129
from systemic mastocytosis, 130
genetics of, 116, 120, 127–128
- Selective estrogen receptors modulators (SERMs), for osteoporosis in men, 208
for postmenopausal osteoporosis, **219–232**
bone mineral density effects, 221–223
bone turnover effects, 102, 220–221
calcitonin therapy and, 281
clinical interest in, 219–220
extraskeletal effects, 226–229
fracture risk effects, 223–226
new developments, 229–230
- Sex. See *Gender*.
- Sex steroids, bone metabolism role of, 195–196, 213
gender non-specificity of, 212–213
in men, 196–208
in women, 208–212
- Single-gene disorders, with osteoporosis, 66
bone mass abnormalities and, 69
linkage analysis in pedigrees, 66–67
- Skeletal disorders, inherited, secondary osteoporosis from, 127–128
- Soy protein, as phytoestrogen source, 234
bone mineral density and, 241–245
clinical trials on, 246, 248–249
mechanism of action, 235–236
ovarian function and, 240–241
- Standard deviation (SD) scores, in various bone measurement devices, for WHO osteoporosis criteria, 159–160, 162–165, 169

Statins, as anabolic therapy, for osteoporosis, 290–291

Steroids, secondary osteoporosis from. See *Glucocorticoid-induced osteoporosis (GIOP)*.

Stiffness, as bone load capacity factor, 26–27, 29

Stress risers, in bone remodeling, 254, 257

Strontium, as anabolic therapy, for osteoporosis, 288–290

Structural basis, of bone strength. See *Biomechanical basis; Bone strength*.

Structural failure, of bones. See *Fracture(s)*.

Surrogate markers, for osteoporosis-specific therapies, 170–176

Synthetic isoflavones, effects on bone markers and density, 249–250

Systemic mastocytosis, secondary osteoporosis from, 130

T

T cells, in bone resorption regulation, 17–18

T-score Equivalency Project, 164–165

T scores, in various bone measurement devices, for gender-related osteoporosis, 197
for WHO osteoporosis criteria, 160–165

Tamoxifen, for postmenopausal osteoporosis, adverse events from, 229
bone mineral density effects, 221–223
bone turnover effects, 220
clinical interest in, 219–220
extraskeletal effects, 226–229
fracture risk effects, 223–224

Tartrate-resistant acid phosphatase 5b (TRACP 5b), as biochemical bone marker, 87–88

Testicular feminization, bone metabolism and, 208–210

Testosterone, bone metabolism role of, gender non-specificity of, 212–213
in men, 196, 204–208
in women, 211
for osteoporosis, glucocorticoid-induced, 144

Thermodegradation, as variable, in bone marker measurements, 90

Thiazide diuretics, for osteoporosis, glucocorticoid-induced, 143

Thyroid disease, secondary osteoporosis from, 120–121

Thyroid hormone, as peak bone mass factor, 55

Tibolone, as anabolic therapy, for osteoporosis, 291

Timing, as variable, in bone marker measurements, 90–91

Tissue mineral density, of bone. See *Bone mineral density (BMD)*.

Tobacco use, as osteoporosis risk factor, 8, 126, 344
as peak bone mass factor, 56

Trabecular bone, aging remodeling of, 28–29, 32–34

Transcription factors, in bone formation regulation, 19–20

Transforming growth factor (TGF), in bone resorption regulation, 17, 20

Transforming growth factor beta-1, osteoporosis susceptibility based on, 75

Transplantations. See *Organ transplantation*.

Tumor necrosis factor (TNF), in bone resorption regulation, 17, 237

Tumor necrosis factor receptor 2, osteoporosis susceptibility based on, 76–77

Turner syndrome, secondary osteoporosis from, 118

U

Ultraviolet radiation, as variable, in bone marker measurements, 90

Uterus, selective estrogen receptors modulators impact on, 227–228

V

Variability, of bone marker measurements, 88–91

Vitamin D, absorption factors of, 340–342
deficiency of, bone remodeling and, 92
secondary osteoporosis from, 117–119, 122–123, 126–127
for osteoporosis, **339–352**

glucocorticoid-induced, 141–143
nasal calcitonin therapy and, 72
physiology of, 340–342
preventive guidelines for, 342,
345
sources of, 349
supportive guidelines for,
345–348
intake recommendations for,
342, 349
normal serum values of, 342
Vitamin D receptor (VDR) genotype, as
peak bone mass factor, 46,
49–50
osteoporosis susceptibility based on,
71–73
Vitamin D supplements, 92, 349

Vitamin K deficiency, osteoporotic fracture
risks and, 99

W

Wnt signaling, in bone formation
regulation, 19–20

World Health Organization (WHO), on
osteoporosis, diagnostic criteria,
159–166
epidemiology perspectives, 1,
4–5

Z

Zoledronate, for osteoporosis, bone
turnover effects, 102–103
guidelines for, 259–260